Are molecular biomarkers of Alzheimer’s disease associated with disease pathology at autopsy?

Takeaway

  • A fully automated electrochemiluminescence assay (ECLIA) of cerebrospinal fluid (CSF) biomarkers detected pathological Alzheimer’s disease (AD) changes with high accuracy.

Why this matters

  • Compared to positron emission tomography (PET), measuring AD biomarkers in CSF and plasma is a more cost effective, accessible, radiation-sparing approach.

  • However, there is large variability in the enzyme-linked immunosorbent assays commonly used to measure these biomarkers, and more standardized, cost-effective methods are needed.